Raymond James Financial
CBIO

Raymond James Financial’s Crescent Biopharma CBIO Stock Holding History

Raymond James Financial’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50
Closed -$807 – 5669
2025
Q2 		$807 Buy
+50
New +$1.06K ﹤0.01% 6601

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Raymond James Financial's CBIO Position: Q3 2025 in Review

Raymond James Financial sold out of Crescent Biopharma (CBIO) in Q3 2025, closing a stake of 50 shares — an estimated $807 sold.

Raymond James Financial first reported a position in CBIO in Q2 2025 and held it in 1 quarter. The position peaked at $807 in Q2 2025. 41 funds tracked by Wall St. Rank hold CBIO as of Q3 2025.

  • Raymond James Financial reported no remaining Crescent Biopharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 50 Crescent Biopharma shares in Q3 2025, an estimated $807.
  • Raymond James Financial first reported a position in Crescent Biopharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Crescent Biopharma position peaked at $807 in Q2 2025.
  • 41 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.